青少年类风湿关节炎患儿的药物治疗。过去、现在与未来。

Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future.

作者信息

Giannini E H, Cawkwell G D

机构信息

Department of Pediatrics, University of Cincinnati, College of Medicine, Ohio, USA.

出版信息

Pediatr Clin North Am. 1995 Oct;42(5):1099-125. doi: 10.1016/s0031-3955(16)40055-6.

DOI:10.1016/s0031-3955(16)40055-6

PMID:7567188

Abstract

Rheumatology made its debut as a legitimate subspecialty of pediatrics sometime in the 1940s in Europe, and in the 1970s in North America. Therapy of juvenile rheumatoid arthritis has evolved from salicylates and gold injections to newer, less toxic nonsteroidal anti-inflammatory drugs and methotrexate. Corticosteroids remain as important drugs when life-threatening complications or blinding iridocyclitis develop. Immune response modifiers and gene therapies offer considerable potential for eventually halting or curing the disease but have yet to make a substantial impact on therapy. Methods for the correct conduct and interpretation of data from clinical trials are discussed.

摘要

20世纪40年代，风湿病学在欧洲首次成为儿科学的一个合法亚专业，20世纪70年代在北美成为合法亚专业。青少年类风湿性关节炎的治疗已从水杨酸盐和金注射剂发展到更新的、毒性较小的非甾体抗炎药和甲氨蝶呤。当出现危及生命的并发症或致盲性虹膜睫状体炎时，皮质类固醇仍然是重要的药物。免疫反应调节剂和基因疗法最终有可能阻止或治愈该疾病，但尚未对治疗产生重大影响。文中讨论了正确开展和解释临床试验数据的方法。